Lung Cancer Stage IV Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Lung Cancer Stage IV clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Non-small Cell Lung Cancer (NSCLC)KRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc.616 enrolled89 locationsNCT06162221
Recruiting
Phase 2

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Lung CancerNon-small Cell Lung CancerNon-Small Cell Lung Cancer (Stage III)+1 more
Case Comprehensive Cancer Center85 enrolled1 locationNCT07104630
Recruiting
Phase 2

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

Non-small Cell Lung CancerNon-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IV+2 more
University of California, Davis56 enrolled1 locationNCT07250477
Recruiting
Early Phase 1

[177Lu]Lu-AKIR001 First-in-human Study

Thyroid Gland Anaplastic CarcinomaPoorly Differentiated Thyroid CarcinomaCancer Head and Neck+3 more
Karolinska University Hospital15 enrolled1 locationNCT06639191
Recruiting
Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Non-small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-Small Cell Lung Cancer (Stage III)+5 more
Genelux Corporation142 enrolled16 locationsNCT06463665
Recruiting

Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohor

Lung Cancer Stage IV
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1,000 enrolled3 locationsNCT06076005
Recruiting
Not Applicable

The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer

Lung Cancer Stage IV
Lithuanian University of Health Sciences120 enrolled1 locationNCT06000358